# Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

> **NCT03098953** · PHASE1 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Loteprednol Etabonate

## Key facts

- **NCT ID:** NCT03098953
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-10
- **Primary completion:** 2017-05-12
- **Final completion:** 2017-05-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03098953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03098953, "Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03098953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*